Effect of novel therapeutic glucocorticoids on circadian rhythms of hormones and cytokines in rheumatoid arthritis

被引:33
作者
Kirwan, John R. [1 ]
Clarke, Lynsey [1 ]
Hunt, Linda P. [2 ]
Perry, Mark G. [3 ]
Straub, Rainer H. [4 ]
Jessop, David S. [5 ]
机构
[1] Univ Bristol, Bristol Royal Infirm, Acad Rheumatol Unit, Bristol BS2 8HW, Avon, England
[2] Univ Bristol, Dept Clin Sci S Brisol, Bristol BS2 8HW, Avon, England
[3] Derriford Hosp, Plymouth Hosp NHS Trust, Plymouth PL6 8DH, Devon, England
[4] Univ Hosp, Dept Internal Med 1, Lab Neuroendocrinoimmunol, Regensburg, Germany
[5] Univ Bristol, Henry Wellcome Labs Integrated Neurosci & Endocri, Bristol BS2 8HW, Avon, England
来源
NEUROENDOCRINE IMMUNOLOGY IN RHEUMATIC DISEASES: TRANSLATION FROM BASICS TO CLINICS | 2010年 / 1193卷
关键词
IL-6; cortisol; arthritis; PITUITARY-ADRENAL AXIS; CORTISOL PRODUCTION; DISEASE-ACTIVITY; DOUBLE-BLIND; INTERLEUKIN-6; IMMUNE; DEFECT; TRIAL;
D O I
10.1111/j.1749-6632.2009.05289.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The morning stiffness and pain of rheumatoid arthritis (RA) is accompanied by a rise in serum interleukin-6 (IL-6) from 2 am to 7 am. Using a formulation that releases prednisone at 2 am (after ingestion at 10 pm), we studied the circadian dynamics of serum IL-6, other cytokines, and cortisol in 9 patients before and after 2 weeks, therapy. Significant improvements occurred in morning stiffness, pain, disease activity, and the acute-phase response. Only IL-6 showed measurable cytokine circadian variation, its high pretreatment peak was abolished, and changes in IL-6 correlated with the changes in morning stiffness. Following treatment, afternoon and evening serum cortisol was reduced, but in the early morning cortisol peak concentration increased. Thus the severity of morning symptoms is related to nocturnal serum IL-6 concentration. The specific timing of the medication, linked to the interaction between IL-6 and the hypothalamic-pituitary-adrenal (HPA) axis, may correct a postulated deficiency in HPA control in RA.
引用
收藏
页码:127 / 133
页数:7
相关论文
共 48 条
  • [31] Therapeutic effect of an altered peptide ligand derived from heat-shock protein 60 by suppressing of inflammatory cytokines secretion in two animal models of rheumatoid arthritis
    Lorenzo, N.
    Barbera, A.
    Dominguez, M. C.
    Torres, A. M.
    Hernandez, M. V.
    Hernandez, I.
    Gil, R.
    Ancizar, J.
    Garay, H.
    Reyes, O.
    Altruda, F.
    Silengo, L.
    Padron, G.
    AUTOIMMUNITY, 2012, 45 (06) : 449 - 459
  • [32] Novel Biomarkers, Diagnostic and Therapeutic Approach in Rheumatoid Arthritis Interstitial Lung Disease-A Narrative Review
    Florescu, Alesandra
    Gherghina, Florin Liviu
    Musetescu, Anca Emanuela
    Padureanu, Vlad
    Rosu, Anca
    Florescu, Mirela Marinela
    Criveanu, Cristina
    Florescu, Lucian-Mihai
    Bobirca, Anca
    BIOMEDICINES, 2022, 10 (06)
  • [33] Translation Research in Therapeutic Approaches from Conventional to Novel Nano-therapeutics for Rheumatoid Arthritis Treatment
    Rani, Laxmi
    Mathur, Pooja
    Verma, Ravinder
    Kumar, Vivek
    Mishra, Ashwini Kumar
    Sahoo, Pravat Kumar
    CURRENT RHEUMATOLOGY REVIEWS, 2025, 21 (01) : 37 - 53
  • [34] Mucosa-associated lymphoid tissue lymphoma translocation 1 as a novel therapeutic target for rheumatoid arthritis
    Lee, Chang Hoon
    Bae, Su Jeong
    Kim, Miok
    SCIENTIFIC REPORTS, 2017, 7
  • [35] Glucocorticoids in Early Rheumatoid Arthritis: Are the Benefits of Joint-Sparing Effects Offset by the Adverse Effect of Osteoporosis? The Effects on Bone in the Utrecht Study and the CAMERA-II Study
    Jacobs, Johannes W. G.
    Bijlsma, Johannes W. J.
    van Laar, Jacob M.
    NEUROIMMUNOMODULATION, 2015, 22 (1-2) : 66 - 71
  • [36] The effect of glucocorticoids on bone mineral density in patients with rheumatoid arthritis: A systematic review and meta-analysis of randomized, controlled trials
    Blavnsfeldt, Anne-Birgitte Garm
    de Thurah, Annette
    Thomsen, Malissa Dawn
    Tarp, Simon
    Langdahl, Bente
    Hauge, Ellen-Margrethe
    BONE, 2018, 114 : 172 - 180
  • [37] Therapeutic effect of the immunomodulatory drug lenalidomide, but not pomalidomide, in experimental models of rheumatoid arthritis and inflammatory bowel disease
    Lopez-Millan, Belen
    Diaz de la Guardia, Rafael
    Roca-Ho, Heleia
    Garcia-Herrero, Carmen M.
    Lavoie, Jessie R.
    Rosu-Myles, Michael
    Gonzalez-Rey, Elena
    O'Valle, Francisco
    Criado, Gabriel
    Delgado, Mario
    Menendez, Pablo
    EXPERIMENTAL AND MOLECULAR MEDICINE, 2017, 49
  • [38] CXCR4-targeted PET imaging in rheumatoid arthritis: a novel approach for monitoring disease activity and therapeutic response
    Han, Ya
    Cao, Shuo
    Liu, Jie
    Ding, Binbin
    Wang, Shijie
    Pan, Jihong
    Ge, Yongpeng
    Cheng, Kai
    Wang, Lin
    Ge, Luna
    EJNMMI RESEARCH, 2025, 15 (01):
  • [39] Salicylalazine: A novel therapeutic agent targeting TLR4/NLRP3/ GSDMD-mediated pyroptosis in rheumatoid arthritis
    Qasim, Sumera
    Al-Joufi, Fakhria A.
    Uttra, Ambreen Malik
    Afzal, Hafiza Sara
    Ahmed, Shaimaa R.
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2025, 145
  • [40] Therapeutic effect of Cryptotanshinone on experimental rheumatoid arthritis through downregulating p300 mediated-STAT3 acetylation
    Wang, Ying
    Zhou, Chun
    Gao, Hui
    Li, Cuixian
    Li, Dong
    Liu, Peiqing
    Huang, Min
    Shen, Xiaoyan
    Liu, Liang
    BIOCHEMICAL PHARMACOLOGY, 2017, 138 : 119 - 129